| Year |
Citation |
Score |
| 2021 |
Ghonime MG, Saini U, Kelly MC, Roth JC, Wang PY, Chen CY, Miller K, Hernandez-Aguirre I, Kim Y, Mo X, Stanek JR, Cripe T, Mardis E, Cassady KA. Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy. Journal For Immunotherapy of Cancer. 9. PMID 34599026 DOI: 10.1136/jitc-2021-002939 |
0.315 |
|
| 2020 |
Ghonime MG, Roth JC, Barker NJ, Miller KE, Mardis ER, Walker CM, Cassady KA. Abstract A15: Improving immune recognition of shared tumor-associated antigens in pediatric tumors using a multimodal oncolytic virus Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-A15 |
0.335 |
|
| 2019 |
Cassady K, Miller K, Prasad N, Maric D, Bernstock J, Roth J, Barker N, Coleman J, Schieffer K, Leraas K, Miller A, Leavenworth J, Cutter G, Whitley R, Roizman B, et al. ATIM-32. PREDICTORS OF IMPROVED SURVIVAL FOLLOWING ONCOLYTIC VIRUS TREATMENT IN PATIENTS WITH RECURRENT GLIOBLASTOMA: GENE EXPRESSION ANALYSIS FROM THE PHASE IB G207 CLINICAL TRIAL Neuro-Oncology. 21: vi8-vi8. DOI: 10.1093/Neuonc/Noz175.031 |
0.329 |
|
| 2017 |
Ghonime MG, Jackson J, Shah A, Roth J, Li M, Saunders U, Coleman J, Gillespie GY, Markert JM, Cassady KA. Chimeric HCMV/HSV-1 and Δγ134.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory. Translational Oncology. 11: 86-93. PMID 29216507 DOI: 10.1016/J.Tranon.2017.10.005 |
0.349 |
|
| 2017 |
Cassady KA, Bauer DF, Roth J, Chambers MR, Shoeb T, Coleman J, Prichard M, Gillespie GY, Markert JM. Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates. Molecular Therapy Oncolytics. 5: 1-10. PMID 28345027 DOI: 10.1016/J.Omto.2017.02.001 |
0.311 |
|
| 2015 |
Roth JC, Alberti MO, Ismail M, Lingas KT, Reese JS, Gerson SL. MGMT enrichment and second gene co-expression in hematopoietic progenitor cells using separate or dual-gene lentiviral vectors. Virus Research. 196: 170-80. PMID 25479595 DOI: 10.1016/J.Virusres.2014.11.027 |
0.605 |
|
| 2014 |
Jackson JD, McMorris AM, Roth JC, Coleman JM, Whitley RJ, Gillespie GY, Carroll SL, Markert JM, Cassady KA. Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines. Gene Therapy. 21: 984-90. PMID 25119379 DOI: 10.1038/Gt.2014.72 |
0.407 |
|
| 2014 |
Smith TT, Roth JC, Friedman GK, Gillespie GY. Oncolytic viral therapy: targeting cancer stem cells. Oncolytic Virotherapy. 2014: 21-33. PMID 24834430 DOI: 10.2147/OV.S52749 |
0.334 |
|
| 2013 |
Gaston DC, Odom CI, Li L, Markert JM, Roth JC, Cassady KA, Whitley RJ, Parker JN. Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1. Plos One. 8: e81768. PMID 24312353 DOI: 10.1371/Journal.Pone.0081768 |
0.376 |
|
| 2013 |
Sawant A, Schafer CC, Jin TH, Zmijewski J, Tse HM, Roth J, Sun Z, Siegal GP, Thannickal VJ, Grant SC, Ponnazhagan S, Deshane JS. Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways. Cancer Research. 73: 6609-20. PMID 24085788 DOI: 10.1158/0008-5472.Can-13-0987 |
0.405 |
|
| 2013 |
Alberti MO, Deshane JS, Chaplin DD, Pereboeva L, Curiel DT, Roth JC. A myeloid cell-binding adenovirus efficiently targets gene transfer to the lung and escapes liver tropism. Gene Therapy. 20: 733-41. PMID 23171918 DOI: 10.1038/Gt.2012.91 |
0.393 |
|
| 2012 |
Roth JC, Ismail M, Reese JS, Lingas KT, Ferrari G, Gerson SL. Cotransduction with MGMT and Ubiquitous or Erythroid-Specific GFP Lentiviruses Allows Enrichment of Dual-Positive Hematopoietic Progenitor Cells In Vivo. Isrn Hematology. 2012: 212586. PMID 22888445 DOI: 10.5402/2012/212586 |
0.62 |
|
| 2012 |
Alberti MO, Roth JC, Ismail M, Tsuruta Y, Abraham E, Pereboeva L, Gerson SL, Curiel DT. Derivation of a myeloid cell-binding adenovirus for gene therapy of inflammation. Plos One. 7: e37812. PMID 22624065 DOI: 10.1371/Journal.Pone.0037812 |
0.578 |
|
| 2011 |
Lin Y, Cheung P, Roth JC, Wilson DL, Gerson SL. Imaging stem cell-derived persistent foci after in vivo selection of lentiviral MGMT-P140K transduced murine bone marrow cells. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1342-52. PMID 21304493 DOI: 10.1038/Mt.2010.315 |
0.581 |
|
| 2010 |
Komarova S, Roth J, Alvarez R, Curiel DT, Pereboeva L. Targeting of mesenchymal stem cells to ovarian tumors via an artificial receptor. Journal of Ovarian Research. 3: 12. PMID 20500878 DOI: 10.1186/1757-2215-3-12 |
0.349 |
|
| 2010 |
Li J, Fatima A, Komarova S, Ugai H, Uprety P, Roth JC, Wang M, Oster RA, Curiel DT, Matthews QL. Evaluation of adenovirus capsid labeling versus transgene expression. Virology Journal. 7: 21. PMID 20102632 DOI: 10.1186/1743-422X-7-21 |
0.41 |
|
| 2008 |
Paul CP, Everts M, Glasgow JN, Dent P, Fisher PB, Ulasov IV, Lesniak MS, Stoff-Khalili MA, Roth JC, Preuss MA, Dirven CM, Lamfers ML, Siegal GP, Zhu ZB, Curiel DT. Characterization of infectivity of knob-modified adenoviral vectors in glioma. Cancer Biology & Therapy. 7: 786-93. PMID 18756624 DOI: 10.4161/Cbt.7.5.5421 |
0.412 |
|
| 2008 |
Roth JC, Curiel DT, Pereboeva L. Cell vehicle targeting strategies Gene Therapy. 15: 716-729. PMID 18369326 DOI: 10.1038/Gt.2008.38 |
0.428 |
|
| 2008 |
Gao Y, Lobritz MA, Roth J, Abreha M, Nelson KN, Nankya I, Moore-Dudley DM, Abraha A, Gerson SL, Arts EJ. Targets of small interfering RNA restriction during human immunodeficiency virus type 1 replication. Journal of Virology. 82: 2938-51. PMID 18199654 DOI: 10.1128/Jvi.02126-07 |
0.436 |
|
| 2008 |
Reese JS, Roth JC, Gerson SL. Bone marrow-derived cells exhibiting lung epithelial cell characteristics are enriched in vivo using methylguanine DNA methyltransferase-mediated drug resistance. Stem Cells (Dayton, Ohio). 26: 675-81. PMID 18192231 DOI: 10.1634/Stemcells.2007-0803 |
0.577 |
|
| 2007 |
Pereboeva L, Komarova S, Roth J, Ponnazhagan S, Curiel DT. Targeting EGFR with metabolically biotinylated fiber-mosaic adenovirus Gene Therapy. 14: 627-637. PMID 17251987 DOI: 10.1038/Sj.Gt.3302916 |
0.397 |
|
| 2006 |
An FQ, Folarin HM, Compitello N, Roth J, Gerson SL, McCrae KR, Fakhari FD, Dittmer DP, Renne R. Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. Journal of Virology. 80: 4833-46. PMID 16641275 DOI: 10.1128/Jvi.80.10.4833-4846.2006 |
0.545 |
|
| 2004 |
Reese JS, Roth JC, Gerson SL. Drug Selection Enrichment of Type II Pneumocytes Following Transplant of P140K MGMT Lentiviral Transduced Hematopoietic Stem Cells. Blood. 104: 3594-3594. DOI: 10.1182/Blood.V104.11.3594.3594 |
0.572 |
|
| 2004 |
Roth JC, Ismail M, Ferrari G, Gerson SL. 914. Mutant MGMT Lentivirus Co-Transduction ith a Marker Lentivirus Efficiently Enriches for Dual-Vector Expressing Cells In Vivo Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.820 |
0.613 |
|
| 2002 |
Wadhwa PD, Zielske SP, Roth JC, Ballas CB, Bowman JE, Gerson SL. Cancer gene therapy: scientific basis. Annual Review of Medicine. 53: 437-52. PMID 11818484 DOI: 10.1146/Annurev.Med.53.082901.104039 |
0.621 |
|
| 1999 |
Davis BM, Roth JC, Liu L, Xu-Welliver M, Pegg AE, Gerson SL. Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy. Human Gene Therapy. 10: 2769-78. PMID 10584923 DOI: 10.1089/10430349950016500 |
0.516 |
|
| Show low-probability matches. |